GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curasight AS (XSAT:CURAS) » Definitions » EV-to-EBIT

Curasight AS (XSAT:CURAS) EV-to-EBIT : -4.41 (As of Jun. 02, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Curasight AS EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Curasight AS's Enterprise Value is kr164.12 Mil. Curasight AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-37.20 Mil. Therefore, Curasight AS's EV-to-EBIT for today is -4.41.

The historical rank and industry rank for Curasight AS's EV-to-EBIT or its related term are showing as below:

XSAT:CURAS' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.41   Med: 0   Max: 0
Current: -4.41

XSAT:CURAS's EV-to-EBIT is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 8.875 vs XSAT:CURAS: -4.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Curasight AS's Enterprise Value for the quarter that ended in Mar. 2025 was kr154.56 Mil. Curasight AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-37.20 Mil. Curasight AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -24.07%.


Curasight AS EV-to-EBIT Historical Data

The historical data trend for Curasight AS's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curasight AS EV-to-EBIT Chart

Curasight AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial - -42.23 -8.76 -10.03 -4.26

Curasight AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.63 -6.54 -5.47 -4.26 -4.15

Competitive Comparison of Curasight AS's EV-to-EBIT

For the Biotechnology subindustry, Curasight AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curasight AS's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curasight AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curasight AS's EV-to-EBIT falls into.


;
;

Curasight AS EV-to-EBIT Calculation

Curasight AS's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=164.116/-37.2
=-4.41

Curasight AS's current Enterprise Value is kr164.12 Mil.
Curasight AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-37.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curasight AS  (XSAT:CURAS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Curasight AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-37.2/154.56465279
=-24.07 %

Curasight AS's Enterprise Value for the quarter that ended in Mar. 2025 was kr154.56 Mil.
Curasight AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-37.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curasight AS EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Curasight AS's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Curasight AS Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200
Curasight AS is a clinical-stage biotech company committed to improving both the diagnosis and the treatment of certain types of cancer. The company is focused on generating data with both uTRACE and uTREAT in cancers, including prostate cancer and glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non small cell lung cancer (NSCLC), and pancreatic cancer.

Curasight AS Headlines

No Headlines